Skip to main content
. 2021 Aug;31(8):1381–1394. doi: 10.1101/gr.270066.120

Figure 1.

Figure 1.

Treatment response to HC between Jak2VF mutant and wild-type mice. (A) Mouse study design: wild-type (WT) and JAK2VF mice were treated with HC or VEH for 6 wk, 5 d a week. Dose was maintained at 50 mg/kg/d for 2 wk and then increased to 100 mg/kg/d. After 6 wk, peripheral blood, spleen, and bone marrow were collected for further analyses. Spleens were measured for weight and size. Neutrophils were isolated from peripheral blood and LSK cells from bone marrow to perform RNA-sequencing on both cell types. (B) Mean blood cell counts per mouse group (Jak2VF-HC = 4, Jak2VF-VEH = 4, WT-HC = 7, WT-HC = 8), including white blood cells, platelets, and hematocrit. Data represent the mean ±SD. Statistical analysis performed in HC versus VEH. (*) P ≤ 0.05, (**) P ≤ 0.01, (***) P ≤ 0.001 and (****) P ≤ 0.0001; analysis of variance (ANOVA). (C) Spleen weight and length following 6 wk of HC or VEH treatment. Nonparametric, unpaired Mann–Whitney U test. Error bars indicate mean with SD. (D) Representative examples of spleens (preserved in 10% formaldehyde) for each group. Length given corresponds to measurements on fresh tissue.